CRVO vs. RAPT, CTMX, MCRB, CYBN, RPTX, PRLD, INCR, RGLS, IMAB, and PRQR
Should you be buying CervoMed stock or one of its competitors? The main competitors of CervoMed include RAPT Therapeutics (RAPT), CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), Cybin (CYBN), Repare Therapeutics (RPTX), Prelude Therapeutics (PRLD), InterCure (INCR), Regulus Therapeutics (RGLS), I-Mab (IMAB), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical preparations" industry.
RAPT Therapeutics (NASDAQ:RAPT) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends.
RAPT Therapeutics received 85 more outperform votes than CervoMed when rated by MarketBeat users. However, 100.00% of users gave CervoMed an outperform vote while only 66.17% of users gave RAPT Therapeutics an outperform vote.
RAPT Therapeutics currently has a consensus target price of $24.67, suggesting a potential upside of 510.56%. CervoMed has a consensus target price of $57.50, suggesting a potential upside of 138.69%. Given CervoMed's higher possible upside, equities research analysts plainly believe RAPT Therapeutics is more favorable than CervoMed.
99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by company insiders. Comparatively, 2.0% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
CervoMed has higher revenue and earnings than RAPT Therapeutics.
RAPT Therapeutics' return on equity of -45.48% beat CervoMed's return on equity.
In the previous week, RAPT Therapeutics had 1 more articles in the media than CervoMed. MarketBeat recorded 6 mentions for RAPT Therapeutics and 5 mentions for CervoMed. RAPT Therapeutics' average media sentiment score of 1.11 beat CervoMed's score of -0.03 indicating that CervoMed is being referred to more favorably in the news media.
RAPT Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Comparatively, CervoMed has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500.
Summary
CervoMed beats RAPT Therapeutics on 8 of the 15 factors compared between the two stocks.
Get CervoMed News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CervoMed Competitors List
Related Companies and Tools
